Synairgen PLC (LSE:SNG) - Share price


Stock Report

Synairgen PLC SNG

Last Price
GBX154.50

Day Change
0.10|0.06%

As of 22/06/2021
15:19:21 BST | GBX
Minimum 15 Minutes Delay.

Last Close154.40p
Day Range152.00 - 166.00
Mkt Cap308.70Mil
52-Wk Range32.80 - 258.46
Yield %-
ISINGB00B0381Z20
Volume2,144,956
P/E-
P/SInfinity
P/CF-0.10

Share Price

Total Returns 21/06/2021

 Chg (%)  
More ...
Synairgen PLC46.21 
FTSE 100 TR GBP0.78
 
Financials
201820192020
More ...
Income Statement
Turnover0.110.000.00
Operating Profit-4.13-4.82-17.74
Net Profit-3.30-3.89-13.92
Reported EPS-3.45-3.55-9.46
Balance Sheet
Current Assets6.403.5088.16
Non Current Assets0.400.570.39
Total Assets6.804.0788.55
Current Liabilities0.781.693.41
Total Liabilities---
Total Equity6.032.2585.14
Cash Flow
Operating Cash Flow-3.89-3.73-24.73
Net Change in Cash0.44-2.8372.52
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
19/10/2020Exercise of OptionMr Richard James Marsden175.00386,842676,974.00
19/10/2020Exercise of OptionJohn Christopher Ward175.00147,330257,828.00

Company Profile

Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, LOXL2 inhibitor, and others.

Sector

Biotechnology

Index

FTSE AIM All-Share

Next Event 29/09/2021

Half-Yearly Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-20.82
Op Mrgn0.00
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Non-Executive DirectorMr. Iain Peter Murray Buchanan
Non-Executive Director, ChairmanMr. Simon James Blouet Shaw
Non-Executive DirectorDr. David Bruce Campbell
Executive Director, Chief Executive OfficerMr. Richard James Marsden
Non-Executive DirectorProfessor Stephen Townley Holgate, CBE
Executive Director, Chief Scientific OfficerDr. Phillip David Monk
Executive Director, Finance Director and Company SecretaryMr. John Christopher Ward
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.